| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/26/2007 | EP1869225A2 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| 12/26/2007 | EP1869168A1 Method for the delivery of exogenous antigens into the mhc class i presentation pathway of cells |
| 12/26/2007 | EP1869086A1 Methods and compositions for modulating and detecting wisp activity |
| 12/26/2007 | EP1869085A2 Novel anti-plgf antibody |
| 12/26/2007 | EP1869077A2 Q3 sparc deletion mutant and uses thereof |
| 12/26/2007 | EP1868656A1 Bioactive stents for type ii diabetics and methods for use thereof |
| 12/26/2007 | EP1868651A2 Method of inducing neutralizing antibodies to human immunodeficiency virus |
| 12/26/2007 | EP1868650A2 Covalent diabodies and uses thereof |
| 12/26/2007 | EP1868649A2 Elimination of heterogeneous or mixed cell population in tumors |
| 12/26/2007 | EP1868648A2 Methods and compositions for modulating hyperstabilized c-met |
| 12/26/2007 | EP1868647A2 Antibodies that bind ov064 and methods of use therefor |
| 12/26/2007 | EP1868646A2 Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent |
| 12/26/2007 | EP1868645A1 Multivalent pneumococcal polysaccharide-protein conjugate composition |
| 12/26/2007 | EP1868644A1 Therapy of prostate cancer with ctla4 antibodies and hormonal therapy |
| 12/26/2007 | EP1868643A1 Human antibodies with beta-amyloid peptide-binding capacity and their applications |
| 12/26/2007 | EP1868642A2 Cat allergen fusion proteins and uses thereof |
| 12/26/2007 | EP1868641A2 Vaccines against chlamydial infection |
| 12/26/2007 | EP1868640A1 Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease |
| 12/26/2007 | EP1868639A2 Methods of applying ionization radiation for therapy of hiv infection |
| 12/26/2007 | EP1868638A2 Cross-beta structure on microbial organisms |
| 12/26/2007 | EP1868599A1 Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors |
| 12/26/2007 | EP1722819B1 Method for solubilising peptide mixtures |
| 12/26/2007 | EP1615663B1 Agent for treating leishmania infections |
| 12/26/2007 | EP1401869B1 Molecules and methods for inhibiting shedding of kim-1 |
| 12/26/2007 | EP1287024B1 Virulence genes, proteins, and their use |
| 12/26/2007 | EP1265914B1 Wnt-1 related polypeptides, and nucleic acids encoding the same |
| 12/26/2007 | EP1235596B1 Use of lytic toxins and toxin conjugates |
| 12/26/2007 | EP1187634B1 Cell growth inhibition |
| 12/26/2007 | EP0996710B1 Component of bromelain |
| 12/26/2007 | EP0867190B1 Cytotoxin complexes comprising dipeptides |
| 12/26/2007 | EP0778848B1 Agents for inducing apoptosis and applications of said agents in therapy |
| 12/26/2007 | CN101095053A Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (pth) 1-84 |
| 12/26/2007 | CN101094915A Process for the production of an influenza vaccine |
| 12/26/2007 | CN101094868A Humanized anti-beta7 antagonists and uses therefor |
| 12/26/2007 | CN101094862A Hetero-oligomeric HIV envelope proteins |
| 12/26/2007 | CN101094857A Cytotoxic agents comprising new taxanes |
| 12/26/2007 | CN101094688A Multimeric constructs |
| 12/26/2007 | CN101094687A Nutritional composition comprising indigestible oligosaccharides |
| 12/26/2007 | CN101094686A Use of flagellin in tumor immunotherapy |
| 12/26/2007 | CN101094685A Use of flagellin in the immunotherapy of yersinia pestis |
| 12/26/2007 | CN101094594A Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
| 12/26/2007 | CN101092609A Vaccine against mumps containing a JERYL-LYNN virus strain |
| 12/26/2007 | CN101092605A Mutant strain of Brucella bacterin with weak poison, constructing method, and application |
| 12/26/2007 | CN101092457A Human source Fab antibody for anti recombined alkalescent fibroblast growth factor and application |
| 12/26/2007 | CN101092456A Gene engineering antibody of human source neutrality for anti virus H5N1 of bird flu |
| 12/26/2007 | CN101092453A Therapeutic compounds comprised of anti-fc receptor binding agents |
| 12/26/2007 | CN101092450A Heparinase polypeptide epitope combined to molecules in human MIIC ¿CI category |
| 12/26/2007 | CN101091799A Medicine in use for treating gastric cancer, and preparation method |
| 12/26/2007 | CN101091795A Prevention and treatment of synucleinopathic disease |
| 12/26/2007 | CN101091794A Composition in use for preventing and treating metastatic tumor |
| 12/26/2007 | CN100357439C Modified pig propagation and respiratory syndrome virus ORF5 gene and use thereof |
| 12/26/2007 | CN100357430C 纤维蛋白溶解活性多肽 Polypeptide fibrinolytic activity |
| 12/26/2007 | CN100357426C Culture and collection of dermatophagoides pteronyssinus and method for preparing its allergen diagnosis and treatment preparation |
| 12/26/2007 | CN100357325C Preparation method of anti apoA1, apoB antibody and reagent box used for detecting apoAI, apoB |
| 12/25/2007 | US7312321 Antibody to human enzymes of the metalloprotease family |
| 12/25/2007 | US7312320 Neutralizing antibodies and methods of use thereof |
| 12/25/2007 | US7312317 P2Y4 antibodies |
| 12/25/2007 | US7312313 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and tumor disorders |
| 12/25/2007 | US7312311 Attaching substances to microorganisms |
| 12/25/2007 | US7312308 For stimulating release of tumor necrosis factor and/or cellular proliferation/differentiation of chondrocyte/pericyte/endothelial cells by contacting blood with pro-polypeptide; tumor diagnosis |
| 12/25/2007 | US7312064 Expression vector for use as transformation and gene expression tool in genetic engineering; minimum plasmid-based system for the generation of infectious RNA viruses, preferably influenza viruses, from cloned DNA |
| 12/25/2007 | US7312030 Monitoring capability of genetically engineered arterivirus to propagate in cells; viricides; veterinary medicine; genetic vaccines |
| 12/25/2007 | US7311922 comprising antigens and excipients, which increse serological sensitivity of individuals infected with tuberculosis; for use in diagnosis and prevention of tuberculosis infection |
| 12/25/2007 | US7311921 Effective against FIVDix, FIVUK8, FIVBang, FIVAom1, FIVAom2, FIVPet, and FIVShi. |
| 12/25/2007 | US7311920 Virus coat protein/receptor chimeras and methods of use |
| 12/25/2007 | US7311918 Generation of rotavirus subunit proteins for use in vaccines and methods of providing protective immunity to vertebrates, including humans, against rotavirus infection or disease; providing cell-mediated immune response |
| 12/25/2007 | US7311917 Membrane proteins; fusion proteins; vaccines; kits |
| 12/25/2007 | US7311916 targets particular molecules that occur at the cell surface of HIV during viral entry into host cells; humoral response generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells; mechanism of HIV cell entry |
| 12/25/2007 | US7311915 peptide mixture; induce immunology response; gag protein; vaccines |
| 12/25/2007 | US7311914 Contacting a biological sample isolated from a patient with an agent that is specific for a MAGE-A4 HLA-B37 binding peptide, and determining the interaction between the agent and the MAGE-A4 HLA-B37 binding peptide as a determination of cancer |
| 12/25/2007 | US7311913 humanized monoclonal antibodies against human antihemophilic factor, used as antithrombotic agents, for treatment of strokes, ischemia, angina, necrosis, thrombosis, anemia, urogental disorders, thrombocytopenia or restenosis; cardiovascular disorders |
| 12/25/2007 | US7311912 immunoglobulin heavy chain peptides used for delivery of enzymes, antibodies, single chain antigen binding proteins, antigen combining sites, nucleic acids, carbohydrates and lipids to a basolateral factor of an epithelial surfaces; tissue-targeted therapy |
| 12/25/2007 | US7311911 Methods for inhibiting angiogenesis |
| 12/25/2007 | US7311910 Inhibiting interaction of CTLA4(Cytotoxic T-Lymphocyte Antigen 4)positive T cells with B7-1 or B7-2 positive cells by contacting with an antibody or antibody fragment which recognizes and binds an extracellular domain; tissue transplant rejection; graft versus host disease |
| 12/25/2007 | US7311909 PRO4348 antibodies |
| 12/25/2007 | US7311906 Administering anti-TK1 antibody conjugated to cytotoxic agent consisting of pokeweed antiviral protein (PAP), ricin, abrin, gelonin, saporin, and alpha-sarcin; detecting and diagnosing viral infections |
| 12/25/2007 | US7311892 Multidrug multiligand conjugates for targeted drug delivery |
| 12/23/2007 | CA2552996A1 Window period vaccine small interference rnas vaccines for the prevention and treatment of viral respiratory infectious diseases |
| 12/21/2007 | WO2007147118A1 Infection of cells with myxoma virus requires akt activation |
| 12/21/2007 | WO2007147090A2 Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| 12/21/2007 | WO2007147026A2 Ccr2 antagonists for chronic organ transplantation rejection |
| 12/21/2007 | WO2007147001A2 Lyophilized formulations of anti-egfr antibodies |
| 12/21/2007 | WO2007146957A2 Ror1 as a therapeutic target for lung cancer |
| 12/21/2007 | WO2007146847A2 Glycosylation engineered antibody therapy |
| 12/21/2007 | WO2007146417A2 Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity |
| 12/21/2007 | WO2007146414A2 Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
| 12/21/2007 | WO2007146359A2 Sea lice antigen vaccines |
| 12/21/2007 | WO2007146188A2 Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
| 12/21/2007 | WO2007146160A2 Methods for the treatment of renal disease using anti-pdgf-dd antibodies |
| 12/21/2007 | WO2007146132A2 Prevention of hiv infection |
| 12/21/2007 | WO2007146024A2 Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| 12/21/2007 | WO2007145956A2 USE OF TGF-β ANTAGONISTS IN TREATMENT OF PARATHYROID-RELATED DISORDERS |
| 12/21/2007 | WO2007145941A2 Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
| 12/21/2007 | WO2007145862A2 Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
| 12/21/2007 | WO2007145840A2 Compositions and methods for diagnosing and treating cancer |
| 12/21/2007 | WO2007145806A2 Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof |
| 12/21/2007 | WO2007145760A2 Anthrax compositions and methods of use and production |
| 12/21/2007 | WO2007145689A1 Use of alpha-toxin for treating and preventing staphylococcus infections |
| 12/21/2007 | WO2007145658A1 Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais) |
| 12/21/2007 | WO2007145365A1 Therapeutic agent for cancer and method for screening for the same |